Gilead Sciences Inc is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines in areas of unmet medical need, particularly in infectious diseases, oncology, and inflammatory diseases. The company's mission is to advance the care of patients worldwide through groundbreaking research and development. Gilead Sciences Inc employs a strategy focused on leveraging its scientific expertise and robust pipeline to deliver transformative therapies, while also fostering collaborations and partnerships to enhance its operational capabilities and expand access to its life-saving treatments globally.

GILEAD SCIENCES INC

Gilead Sciences reported strong fourth-quarter results, posting adjusted earnings per share (EPS) of $1.90, surpassing expectations. The company’s total revenues reached $7.6 billion, bolstered by significant sales increases in its HIV, oncology, and liver disease treatments. Notably, Gilead’s HIV drug, Biktarvy, experienced a remarkable 21% surge in sales. Looking forward,...

Gilead Sciences Reports Strong Q4 Earnings and Anticipates Continued Growth with Promising Drug Developments